2024-514001-65-00Not yet recruitingPhase 1
Phase I clinical trial of TG4050 combined with nivolumab in patients with Non-Small Cell Lung Cancer.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 28 Jun 2024
- Start date
- 1 Jan 2025
- Lead sponsor
- Transgene
- Diseases
- Lung cancer
- EU CT number
- 2024-514001-65-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer. It tests TG4050 combined with nivolumab.
- Age
- 18 years or older
- Sex
- Women and men can join.
Main reasons for not taking part
- Healthy volunteers cannot join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Curie | Paris | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.